Biocartis to raise €60m in ABB for research and development
Biocartis, the Belgian developer of molecular diagnostics systems, has launched a €60m accelerated capital increase to finance product development, sales and marketing and the expansion of its manufacturing capacities.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts